Please Wait a Moment
X

Articles

27Jul

Bio-Rad Geenius HIV 1/2 Implementation

27 Jul, 2020 | Return|

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

World Patient Safety Day 2020

The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...

Read More >

Update on the Ortho Conversion

At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...

Read More >

Creative Testing Solutions and Grifols Forge New Testing Partnership

Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...

Read More >

Upcoming HCV Testing Algorithm Change

FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...

Read More >

Reminder-Check flights and cargo hours for the Labor Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

FDA Guidance for Industry for Babesia

On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...

Read More >